Article in AIDS (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 1 institution in 1 country.
Sandro SattaDivision of Infectious Diseases.
Cristelle HugoDivision of Infectious Diseases.
Madhav SharmaDivision of Infectious Diseases.
Valerie RezekDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Athanassios KossyvakisDivision of Infectious Diseases.
Shubhendu Sen RoyDivision of Infectious Diseases.
Scott KitchenDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Theodoros KelesidisDivision of Infectious Diseases.
Office of Infectious Diseases · US
Funding
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
Viral Immunology CoreU19AI117941 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SYMONDS, GEOFFREY · 2015 to 2019
$10.6M
UCLA MSD ProgramR25GM055052 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARBER, PAUL HENRY, HASSON, TAMA W. · 1996 to 2021
$9.2M
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIVR01AG059502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI KELESIDIS, THEODOROS · 2018 to 2022
$2.0M
The role of CD4 in macrophage differentiation and functionR01AI078806 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 2009 to 2013
$1.9M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
In vivo modelling of therapeutic strategies for prevention of HIV-related fibrosis and fatty liver disease in chronic treated HIV-1 infectionR21AI136708 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$429k
Targeting Type I Interferon Immune Activation to Control HIV Infection in vivoR21AI110306 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 2014 to 2015
$424k
Humanized mice as a model to study the role of oxidized lipids in HIV-related cardiovascular diseaseR21HL134444 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS, REDDY, SRINIVASA T. · 2016 to 2017
$424k
Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related TendinopathyR43AG059501 · NIA · ZEN-BIO, INC. · PI BUEHRER, BENJAMIN M, LUDLOW, JOHN WILLIAM · 2018 to 2018
$222k
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIVR03AG059462 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$156k
Humanized mice as a model to study novel therapies for HIV-Associated Neurocognitive Disorders (HAND) in elderly HIV-1 infected individualsR03AG056189 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mitoquinone mesylate attenuates brain inflammation in humanized mouse model of chronic HIV infection. · full record | OpenQuestion